ReviewFrontiers in public health2023
Challenge and opportunity for vector control strategies on key mosquito-borne diseases during the COVID-19 pandemic.
Review in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Application of remote sensing and geospatial technologies in predicting vector-borne disease outbreaks.Royal Society open science · 2025Review
- Vector-borne infectious diseases in pregnancy in the era of climate change: A focus on mosquito- and tick-borne pathogens (Review).Experimental and therapeutic medicine · 2025Review
- Eco-friendly bioactives from Nyctanthes arbor-tristis (L.) for targeted control of Aedes aegypti and Culex quinquefasciatus with reduced impact on Toxorhynchites splendens.Scientific reports · 2025Article
- Global hotspots and academic trends of vector-borne diseases in the order Diptera (Arthropoda: Insecta): a bibliometric visualisation.Folia parasitologica · 2025Article
- Review
- Mosquito-borne infectious diseases in northeastern Italy: analysis of social factors influencing risk perception among the population.Frontiers in public health · 2025Article
- Article
- Review
- Challenges in diagnosing common skin conditions among medical students from the United States in Panama.JAAD international · 2024Article
- Tiny Green Army: Fighting Malaria with Plants and Nanotechnology.Pharmaceutics · 2024Review
- Innovative strategies and challenges mosquito-borne disease control amidst climate change.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
Mosquito-borne diseases are major global health problems that threaten nearly half of the world's population. Conflicting resources and infrastructure required by the coronavirus disease 2019 (COVID-19) global pandemic have resulted in the vector control process being more demanding than ever. Although novel vector control paradigms may have been more applicable and efficacious in these challenging settings, there were virtually no reports of novel strategies being developed or implemented during COVID-19 pandemic. Evidence shows that the COVID-19 pandemic has dramatically impacted the implementation of conventional mosquito vector measures. Varying degrees of disruptions in malaria control and insecticide-treated nets (ITNs) and indoor residual spray (IRS) distributions worldwide from 2020 to 2021 were reported. Control measures such as mosquito net distribution and community education were significantly reduced in sub-Saharan countries. The COVID-19 pandemic has provided an opportunity for innovative vector control technologies currently being developed. Releasing sterile or lethal gene-carrying male mosquitoes and novel biopesticides may have advantages that are not matched by traditional vector measures in the current context. Here, we review the effects of COVID-19 pandemic on current vector control measures from 2020 to 2021 and discuss the future direction of vector control, taking into account probable evolving conditions of the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.